FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Runs Phase 1 for a candidate licensed to Lilly and an Australian trial of its own hair-loss candidate while doing joint research with L'Oréal. Also seen: Global approvals · expansion

  • Signed a joint siRNA skin and hair research agreement with L'Oréal. Source
  • Dosed the first patient in the Australian trial of hair-loss candidate OLX104C. Source

Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

OliX Pharmaceuticals

A drug developer using RNA interference (siRNA) to build treatments for metabolic, skin and hair conditions.

OLX75016 (OLX702A)

Phase 1

A MASH and obesity candidate licensed to Eli Lilly in February 2025 in a deal worth up to $630 million; OliX runs the Phase 1 trial in Australia.

OLX104C

Phase 1

A male-pattern hair-loss candidate that lowers androgen receptor expression; dosing of all patients in its Australian Phase 1b trial is complete.

cp-asiRNA

Technology platform

Its in-house siRNA platform, used for the hair-loss candidate OLX104C and other programs.

Completion reported

Dosed the first patient in the Australian Phase 1b/2a trial of OLX104C.

Completion reported

Completed dosing of all patients in the Australian Phase 1b trial of OLX104C.

Official role guide

OliX Pharmaceuticals careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 올릭스, 일라이릴리에 '비만약 후보' 9117억원 규모 기술수출 '잭팟'(종합) ↗더바이오 · Published 2025-02-07 · Sources checked 2026-11-18 · Original unavailable
  2. 올릭스, 로레알 협력부터 자체 탈모 임상까지... 피부·모발 역량 주목 ↗히트뉴스 · Published 2025-12-20 · Sources checked 2026-11-18 · Original unavailable
  3. 로레알도 베팅한 올릭스···탈모신약, 효능 입증 시험대 오른다 ↗뉴스웨이 · Published 2026-08-07 · Sources checked 2026-11-18 · Original unavailable
  4. 올릭스, 릴리 이어 또다시 글로벌 탑티어와 협업…기술력으로 신뢰 확보 ↗메디코파마 · Published 2025-06-10 · Sources checked 2026-11-18 · Original unavailable